[PS4] Presidential Session 4
【E】

[PS4-4] Randomized phase III study of etoposide/cisplatin versus irinotecan/cisplatin in advanced digestive NEC: JCOG1213

^○森実 千種¹, 町田 望², 本間 義崇³, 奥坂 拓志¹, 朴 成和⁴, 加藤 健³, 野村 尚吾⁵, 平岡 伸介⁶, 関根 茂樹⁶, 谷口 浩和⁶, 岡野 尚弘⁷, 山口 研成⁸, 佐藤 琢爾⁹, 池田 公史¹⁰, 水野 伸匡¹¹, 尾阪 将人¹², 片岡 智子¹³, 寺島 雅典¹⁴, 北川 雄光¹⁵, 古瀬 純司⁷ (1.国立がん研究センター中央病院, 2.Department of Gastroenterology, Kanagawa Cancer Center, 3.Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 4.Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5.JCOG Data Center/Operations Office, National Cancer Center Hospital, 6.Department of Diagnostic Pathology, National Cancer Center Hospital, 7.Department of Medical Oncology, Kyorin University Faculty of Medicine, 8.Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 9.Department of Gastroenterological Surgery, Kochi Health Sciences Center, 10.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 11.Department of Gastroenterology, Aichi Cancer Center Hospital, 12.Hepato-Biliary-Pancreatic Medicine Department, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 13.Japan Clinical Oncology Group Operations Office, Clinical Research Support Office, National Cancer Center Hospital, 14.Division of Gastric Surgery, Shizuoka Cancer Center, 15.Department of Surgery, Keio University School of Medicine.)